Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc (CLDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,139
  • Shares Outstanding, K 26,464
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,220 K
  • EBIT $ -40 M
  • EBITDA $ -38 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.05
  • Most Recent Earnings $-0.65 on 11/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6823 +11.53%
on 01/22/25
1.5300 -50.26%
on 12/26/24
-0.6490 (-46.03%)
since 12/23/24
3-Month
0.6823 +11.53%
on 01/22/25
3.8900 -80.44%
on 11/13/24
-0.0691 (-8.32%)
since 10/23/24
52-Week
0.6823 +11.53%
on 01/22/25
16.8000 -95.47%
on 02/26/24
-9.2390 (-92.39%)
since 01/23/24

Most Recent Stories

More News
Calidi Biotherapeutics (NYSE American: CLDI) to Present Virotherapy Platform at AACR 2025

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, “Development of a Systemic Enveloped Virotherapy...

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per...

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics (NYSE American: CLDI) Announces Public Offering of Common Stock, Warrants

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants...

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics Announces Proposed Public Offering

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation

Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight...

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing...

CLDI : 0.7610 (-0.39%)
Calidi Biotherapeutics (NYSE American: CLDI) Shares Data Supporting Proprietary Systemic Antitumor Platform

T he American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United...

CLDI : 0.7610 (-0.39%)

Business Summary

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 0.8523
2nd Resistance Point 0.8177
1st Resistance Point 0.7893
Last Price 0.7610
1st Support Level 0.7263
2nd Support Level 0.6917
3rd Support Level 0.6633

See More

52-Week High 16.8000
Fibonacci 61.8% 10.6430
Fibonacci 50% 8.7411
Fibonacci 38.2% 6.8393
Last Price 0.7610
52-Week Low 0.6823

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar